Shilpa Medicare Ltd (SHILPAMED) is currently trading at 926.75 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Shilpa Medicare Limited is an Indian pharmaceutical company specializing in APIs, formulations, and biologics, with a global presence in over 50 countries. In 3Q FY26, Shilpa achieved its highest quarterly revenue of INR 411 crores, marking a 28% growth YoY, driven by significant advances in the formulation and biologics segments. The company has launched NorUDCA, a first-in-class therapy for Non-Alcoholic Fatty Liver Disease (NAFLD), through strategic partnerships, enhancing its domestic market position and preparing for international regulatory approvals. Shilpa's focus on differentiated, high-value products and integrated CDMO solutions is supported by a strategic partnership with Orion Corporation and advanced pipeline developments in biosimilars and recombinant human albumin. Substantial investments in R&D and manufacturing capacity expansions have led to marked improvements in the company's adjusted ROCE and underline its commitment to innovative healthcare offerings.

Over the past 52 weeks, Shilpa Medicare Ltd has traded between a low of ₹260.00 and a high of ₹980.65. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Shilpa Medicare Ltd has a market capitalization of approximately 18,812.04. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Shilpa Medicare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 63.27 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 18,812.04 Cr, Shilpa Medicare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Shilpa Medicare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Shilpa Medicare Ltd is 63.27. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

CDSCO granted final marketing authorization for OERIS, an extended-release ondansetron injection developed by Shilpa Medicare for chemotherapy-induced nausea and vomiting (CINV).

The board met on August 5, 2026 to approve the unaudited standalone and consolidated results for the quarter ended June 30, 2026.

The dataset states the board met on August 5, 2026 to approve the unaudited results for the quarter ended June 30, 2026.

The stock rose after Shilpa disclosed an exclusive Europe commercialisation deal with Orion for Recombinant Human Albumin and reported record quarterly revenue and EBITDA with margins around 30%.